Triple-negative breast cancers, which are more frequently diagnosed in younger women, are a subtype of breast tumor characterized by the absence of hormone receptors and HER2 overexpression. As a result, they do not respond ...
5 hours ago
0
3
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more ...
14 hours ago
0
4
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results ...
17 hours ago
0
4
A collaborative clinical study led by National Taiwan University Hospital (NTUH) and Taiwan Clinical Oncology Group, National Health Research Institutes (TCOG, NHRI) has yielded promising results for a new therapeutic regimen ...
Aug 26, 2026
0
3
New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves outcomes for some patients with locally advanced non-small cell lung cancer, according to the results ...
Apr 21, 2026
0
9
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention ...
Jan 12, 2026
0
17
Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published in Cancer.
Dec 8, 2025
0
18
The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for treating adult patients with resectable, ...
Dec 3, 2025
0
12
Clinical data demonstrate the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small ...
Sep 8, 2025
0
39
Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation ...
Sep 8, 2025
0
11
